Canada makes deal with Novavax to produce its COVID-19 vaccine in Canada: PM
Source: CTV News
OTTAWA — Prime Minister Justin Trudeau says a deal has been struck with Novavax to produce its COVID-19 vaccine in Canada, but the pharmaceutical company won’t be ready to roll out doses for several months.
The federal government has signed a “memorandum of understanding” with Novavax to pursue options to produce its COVID-19 vaccine at a new Montreal facility that is under construction.
While the prime minister is calling this a “major step forward,” it could be months before this potential first made-in-Canada vaccine candidate is approved, let alone shipped to delivery sites nationwide. This is because the new National Research Council biomanufacturing facility where the production will happen isn’t set to be completed until July.
Once the new facility is up and running, it’s designed to produce around two million doses a month and, should the Novavax vaccine be deemed safe and effective, Trudeau says “tens of millions” of doses will be made domestically. The facility will not be able to produce MRNA vaccines, however, which are the kind of vaccines Pfizer-BioNTech and Moderna are supplying.
The federal government has a deal with the Maryland-based company to purchase up to 76 million doses of its vaccine candidate.